KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Accumulated Expenses: 2011-2025

Historic Accumulated Expenses for Travere Therapeutics (TVTX) over the last 14 years, with Sep 2025 value amounting to $105.8 million.

  • Travere Therapeutics' Accumulated Expenses rose 26.03% to $105.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.8 million, marking a year-over-year increase of 26.03%. This contributed to the annual value of $86.0 million for FY2024, which is 27.70% down from last year.
  • Latest data reveals that Travere Therapeutics reported Accumulated Expenses of $105.8 million as of Q3 2025, which was up 29.48% from $81.7 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Accumulated Expenses peaked at $139.6 million during Q1 2024, and registered a low of $46.5 million during Q1 2021.
  • Its 3-year average for Accumulated Expenses is $94.8 million, with a median of $86.0 million in 2024.
  • As far as peak fluctuations go, Travere Therapeutics' Accumulated Expenses surged by 62.75% in 2024, and later slumped by 44.76% in 2025.
  • Quarterly analysis of 5 years shows Travere Therapeutics' Accumulated Expenses stood at $75.2 million in 2021, then rose by 27.35% to $95.7 million in 2022, then increased by 24.28% to $119.0 million in 2023, then dropped by 27.70% to $86.0 million in 2024, then rose by 26.03% to $105.8 million in 2025.
  • Its Accumulated Expenses stands at $105.8 million for Q3 2025, versus $81.7 million for Q2 2025 and $77.1 million for Q1 2025.